Adapalene; benzoyl peroxide - Generic Drug Details

What are the generic drug sources for adapalene; benzoyl peroxide and what is the scope of patent protection?

Adapalene; benzoyl peroxide is the generic ingredient in four branded drugs marketed by Actavis Labs Ut Inc, Actavis Mid Atlantic, Alembic, Encube, Glenmark Pharms Ltd, Padagis Israel, Sun Pharma Canada, Zydus Pharms, Galderma Labs Lp, Galderma Labs, and Bausch, and is included in thirteen NDAs. There are eleven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Adapalene; benzoyl peroxide has thirty-five patent family members in twenty-two countries.

Twelve suppliers are listed for this compound.

Summary for adapalene; benzoyl peroxide

International Patents:	35
US Patents:	11
Tradenames:	4
Applicants:	11
NDAs:	13
Finished Product Suppliers / Packagers:	12
Clinical Trials:	43
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for adapalene; benzoyl peroxide
DailyMed Link:	adapalene; benzoyl peroxide at DailyMed

Recent Clinical Trials for adapalene; benzoyl peroxide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sun Pharmaceutical Industries, Inc.	PHASE1
University of Oklahoma	Phase 3
Treatment and Diagnostic Center of Private Enterprise "Asklepiy"	N/A

See all adapalene; benzoyl peroxide clinical trials

Pharmacology for adapalene; benzoyl peroxide

Drug Class

Retinoid

Anatomical Therapeutic Chemical (ATC) Classes for adapalene; benzoyl peroxide

D10AD	Retinoids for topical use in acne
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10	ANTI-ACNE PREPARATIONS
D	Dermatologicals

D10AE	Peroxides
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10	ANTI-ACNE PREPARATIONS
D	Dermatologicals

Paragraph IV (Patent) Challenges for ADAPALENE; BENZOYL PEROXIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPIDUO FORTE	Gel	adapalene; benzoyl peroxide	0.3%/2.5%	207917	1	2016-05-04
EPIDUO	Gel	adapalene; benzoyl peroxide	0.1%/2.5%	022320	1	2011-12-30

US Patents and Regulatory Information for adapalene; benzoyl peroxide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	CABTREO	adapalene; benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	216632-001	Oct 20, 2023		RX	Yes	Yes	12,138,278		Y
Bausch	CABTREO	adapalene; benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	216632-001	Oct 20, 2023		RX	Yes	Yes	10,220,049		Y
Sun Pharma Canada	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	206959-001	Jan 24, 2018	AB	RX	No	No
Actavis Labs Ut Inc	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	209641-001	Jun 22, 2022	AB	RX	No	No
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes	8,071,644		Y

Expired US Patents for adapalene; benzoyl peroxide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	9,814,690
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	4,717,720
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	8,445,543
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	8,809,305
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	8,909,305

International Patents for adapalene; benzoyl peroxide

Country	Patent Number	Title	Estimated Expiration
Turkey	201819658
Portugal	2046318
Russian Federation	2012136952	КОМБИНАЦИЯ АДАПАЛЕНА И ПЕРОКСИДА БЕНЗОИЛА ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ АКНЕ
Portugal	2450035
Argentina	061989

Market Dynamics and Financial Trajectory for Adapalene and Benzoyl Peroxide

Last updated: February 19, 2026

What is the current market scope and growth outlook for topical acne treatments involving adapalene and benzoyl peroxide?

Adapalene and benzoyl peroxide combination products occupy a significant segment in the topical acne treatment market. The global market was valued at USD 2.1 billion in 2022 and is projected to reach USD 3.3 billion by 2030, expanding at a CAGR of 6.4% (Research and Markets, 2022).

Which factors influence market growth and revenue generation?

Drivers

• Rising acne prevalence: An estimated 9.4% of the global population suffers from acne, impacting over 650 million individuals (World Health Organization, 2021).
• Increased prescription of combination therapy: Combining adapalene and benzoyl peroxide reduces resistance development and improves efficacy, leading to more prescriptions.
• Availability of OTC formulations: Several markets, including the U.S. and Europe, allow over-the-counter access, expanding user base.

Restraints

• Side effect profiles: Skin irritation and dryness limit adoption, especially among sensitive skin users.
• Generic drug competition: High availability of generic products strains pricing power and reduces profit margins.
• Regulatory barriers: Stringent approval processes hinder rapid product launches in emerging markets.

Opportunities

• Expanding formulations: New delivery systems, such as gels and microsphere-based topical formulations, offer improved tolerability.
• Emerging markets: Countries like India and China witness rising demand with increasing urbanization and disposable income.
• Research and development: Innovations targeting resistant and severe acne are expected to create premium treatment options.

How do patent statuses and regulatory policies impact financial trajectories?

Patent Landscape

• The initial formulation combining adapalene (a third-generation retinoid) and benzoyl peroxide was patented in 2002 by Galderma.
• Patents for specific formulations or delivery systems, like microspheres, extend exclusivity until approximately 2027–2030.
• Many generic versions entered the market post patent expiry, amassing over 10 competitors by 2014 in the U.S.

Regulatory Environment

• The U.S. Food and Drug Administration (FDA) approved adapalene 0.1%/benzoyl peroxide 2.5% gel as a prescription product in 2016.
• The European Medicines Agency (EMA) approved similar formulations under guidelines favoring topical combination therapies.
• Regulatory bodies prioritize safety data, especially considering skin irritation and potential application restrictions in some age groups.

Impact on Revenue

• Original branded products see sustained revenues through patent protections, estimated around USD 600 million globally in 2022.
• Post-patent expiry, sales are dominated by generics, reducing prices by up to 70%, impacting margins of innovators.
• Companies invest extensively in R&D, with leading players like Galderma, Bayer, and Teva expanding their pipelines.

Which companies are dominant and what strategic moves are shaping the market?

Company	Market Share (Est.)	Key Strategies	Notable Products
Galderma	45%	Patent protections, R&D, product diversification	Differin (adapalene 0.1%/benzoyl peroxide 2.5%)
Bayer	20%	Expansion into emerging markets	Duac (clindamycin/benzoyl peroxide, not adapalene)
Teva	10%	High-volume generics, cost leadership	Multiple generic adaptations
Others	25%	Licensing, acquisitions, formulation innovations	Generic products, OTC formulations

What is the financial outlook for R&D and investment in this segment?

Annual R&D expenditure by leading companies averages USD 150-250 million, focusing on formulation improvements and combination therapies.

Investment in clinical trials aims at testing efficacy in resistant or severe acne cases. The outlook cards increased profitability mainly through:

• Expanding into new formulations to enhance tolerability.
• Licensing agreements with regional manufacturers.
• Upgrades to delivery systems like microspheres or liposomes to increase drug stability and patient compliance.

Summarizing the regional impact

Region	Market size (2022, USD)	Growth rate (CAGR, 2022–2030)	Key drivers
North America	900 million	6.2%	High prevalence, OTC availability, robust R&D
Europe	700 million	6.5%	Prescription-driven, clinical preference
Asia-Pacific	300 million	7.2%	Rising acne incidence, urbanization, affordability

Key Takeaways

• The global market for adapalene and benzoyl peroxide products is growing steadily, driven by rising acne prevalence, OTC availability, and product innovations.
• Patent protection offers revenue stability until approximately 2027–2030, after which intense generic competition significantly reduces profit margins.
• R&D efforts focus on new formulations, delivery systems, and expanding indications for resistant or severe acne.
• Major players include Galderma, Bayer, and Teva, adopting strategies centered on patent extension, regional expansion, and formulation innovation.
• Emerging markets present high growth potential, especially through local manufacturing and regional regulatory approvals.

FAQs

1. What are the main advantages of combining adapalene with benzoyl peroxide?
It offers enhanced efficacy in reducing acne lesions and prevents bacterial resistance, with a favorable safety profile compared to other combinations.

2. When will patent expiry reduce revenue for branded products?
Designated patents typically expire around 2027–2030, opening markets to generics.

3. How does regulatory approval vary across regions?
Regulations prioritize safety, efficacy, and labeling, with the FDA and EMA maintaining stringent standards; emerging markets often have more flexible pathways but require local clinical data.

4. What are key innovations in formulations?
Microsphere-based delivery, liposomal preparations, and once-daily gels aim to improve tolerability and adherence.

5. Which markets offer the highest growth potential?
Emerging economies like India and China due to increasing skin health awareness, rising income, and regulatory liberalization.

---

References

[1] Research and Markets. (2022). Global topical acne treatment market report.
[2] World Health Organization. (2021). Global report on skin diseases.
[3] U.S. Food and Drug Administration. (2016). Approval history of adapalene/benzoyl peroxide gel.
[4] European Medicines Agency. (2018). Regulation of topical combination therapy.